欧洲新生血管性年龄相关性黄斑变性患者由阿柏西普转换为雷珠单抗的解剖与功能结局:SAFARI研究
SAFARI是一项在英国和德国开展的6个月前瞻性单臂研究,纳入100例对阿柏西普持续或复发病灶活动的新生血管性年龄相关性黄斑变性患者,其中原发性治疗失败1例、次优治疗反应99例。转换为雷珠单抗0.5mg每月注射3次后按需给药,第90天中心子区视网膜厚度中位数较基线显著下降30.75µm(95%CI -59.50至-20.50;p<0.0001),但最佳矫正视力平均改善较小(≤2个字母)。作者认为对阿柏西普次优反应的患者可能从转换中获益。
要点
- 转换为雷珠单抗后第90天中心子区视网膜厚度中位数较基线下降30.75µm(95%CI -59.50至-20.50;p<0.0001)。
- 第90天和第180天分别有55%和59%的患者最佳矫正视力较基线获得0至≥15个字母。
- 各时间点最佳矫正视力平均改善较小(≤2个字母),未发现新的安全性信号。
核心结论
- 由阿柏西普转换为雷珠单抗使中心子区视网膜厚度显著改善,约60%的患者最佳矫正视力稳定或改善。
- 作者认为对阿柏西普显示次优反应的新生血管性年龄相关性黄斑变性患者可能从转换为雷珠单抗中获益。
研究设计与样本
- SAFARI(NCT02161575)是一项在英国和德国开展的6个月前瞻性单臂研究。
- 共纳入100例患者,其中原发性治疗失败1例、次优治疗反应99例。
- 患者接受3次每月玻璃体腔内注射雷珠单抗0.5mg,此后在每月访视时按需给药。
- 主要终点为第90天中心子区视网膜厚度较基线的变化。
主要发现
- 在总体人群中,第90天中心子区视网膜厚度中位数较基线显著下降30.75µm(95%CI -59.50至-20.50;p<0.0001)。
- 其他定量和定性光学相干断层扫描参数也观察到改善。
- 按早期治疗糖尿病视网膜病变研究字母分类评估,第90天和第180天分别有55%和59%的患者较基线获得0至≥15个字母。
- 各时间点最佳矫正视力较基线的平均改善较小(≤2个字母)。
- 未发现新的安全性信号。
关键数值与推荐
- 患者需符合两个亚组之一(原发性治疗失败或次优治疗反应)的严格入选标准。
- 雷珠单抗用法为0.5mg玻璃体腔内注射,每月1次共3次,此后在每月访视时按需给药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Prospective data on switching anti-vascular endothelial growth factors in patients with neovascular age-related macular degeneration (nAMD) who have previously shown no/partial response are limited. This prospective study assessed the effect of switching from aflibercept to ranibizumab on anatomical and functional outcomes in patients with persistent/recurrent disease activity. METHODS: SAFARI (NCT02161575) was a 6-month, prospective, single-arm study conducted in the UK and Germany. Patients, meeting strict eligibility criteria for one of two subgroups (primary treatment failure or suboptimal treatment response), received 3 monthly intravitreal ranibizumab injections (0.5 mg). Thereafter, ranibizumab was administered pro re nata at monthly visits. The primary endpoint was change from baseline (CfB) to day 90 in central subfield retinal thickness (CSRT). Best-corrected visual acuity (BCVA) and retinal morphology parameters were assessed. RESULTS: One hundred patients were enrolled (primary treatment failure, 1; suboptimal treatment response, 99). In the overall population, there was a significant CfB in median CSRT of -30.75 µm (95% CI -59.50,-20.50; p<0.0001) to day 90. Improvements were also observed in other quantitative and qualitative optical coherence tomography parameters. In Early Treatment Diabetic Retinopathy Study letters assessed by category, 55% and 59% of patients gained 0-≥15 letters versus baseline at day 90 and day 180, respectively. However, mean improvements in BCVA (CfB) to each time point were small (≤2 letters). No new safety signals were identified. CONCLUSION: Switching from aflibercept to ranibizumab led to a significant improvement in CSRT, with ~60% experiencing stabilised/improved BCVA. Therefore, patients with nAMD who have shown a suboptimal response to aflibercept may benefit from switching to ranibizumab.
引用
- Gale RP, Pearce I, Eter N, et al. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol. 2019. PMID: 31383649. doi:10.1136/bjophthalmol-2019-314251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。